Respira Therapeutics, Inc.

Respira Therapeutics, Inc. is a health care startup founded in 2010 in the United States. The company focuses on developing inhaled therapeutics for cardiopulmonary diseases, with the aim of improving patient outcomes through enhanced drug targeting to the small airways of the lung. Their proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches set them apart in the industry. Respira's lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is currently in Phase 2 clinical trials. This first-in-class inhaled therapeutic is designed for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients. The company's most recent funding was a Series B investment in November 2015, with Keiretsu Forum Northwest and Rockies participating as investors. Respira Therapeutics' innovative approach to drug delivery and its focus on addressing unmet medical needs in the field of cardiopulmonary diseases position it as a promising player in the health care startup landscape. With these advancements, the company aims to revolutionize the treatment of pulmonary diseases and potentially attract further attention from investors seeking opportunities in the health care sector.